Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Vitrakvi on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Vitrakvi (larotrectinib) is a kinase inhibitor approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion, without a known acquired resistance mutation, that are metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment.
Vitrakvi selectively inhibits TRK (tropomyosin receptor kinase) proteins, blocking abnormal signaling caused by NTRK gene fusions that drive tumor growth, regardless of where in the body the tumor originates — a tumor-agnostic approach based on the underlying genetic alteration.
Vitrakvi is intended for patients of any age, from infants to adults, whose tumors have been confirmed through an approved test to carry an NTRK gene fusion, across a wide range of solid tumor types.
The recommended adult dose of Vitrakvi is 100 mg orally twice daily, with or without food, continued until disease progression or unacceptable toxicity. Pediatric dosing is based on body surface area, using capsules or oral solution as appropriate.
Vitrakvi does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Neurologic reactions, including dizziness, gait disturbances, and cognitive changes, have been reported in a majority of patients in clinical trials. Dose modification may be needed for significant neurotoxicity.
Liver function tests should be monitored every two weeks during the first month of treatment, then monthly thereafter, as liver enzyme elevations have been observed.
Vitrakvi may cause fetal harm. Effective contraception should be used during treatment and for a period after the final dose, as advised by the treating physician.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Vitrakvi is manufactured and marketed by Bayer AG. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating oncologist confirming diagnosis and NTRK gene fusion testing results. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an approved tumor-agnostic therapy for NTRK fusion-positive solid tumors, Vitrakvi is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Vitrakvi directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Vitrakvi should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Vitrakvi through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support oncology care coordination and documentation for Vitrakvi access.
Delhi's major hospitals assist patients with prescription support and documentation for Vitrakvi.
Bangalore's specialist network offers access coordination for eligible NTRK fusion-positive cancer patients seeking Vitrakvi.
Chennai-based oncology specialists coordinate Vitrakvi access alongside comprehensive biomarker-driven cancer care.
Hyderabad's care institutions support patients pursuing Vitrakvi therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Vitrakvi.
Pune-based specialists assist with prescription support and Vitrakvi treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Vitrakvi.
Kochi's specialist units assist patients with the documentation needed for Vitrakvi access.
Chandigarh's care centers support Vitrakvi treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Vitrakvi access process.
Lucknow-based centers assist patients pursuing Vitrakvi therapy.
Bhubaneswar's institutions support access to Vitrakvi for eligible patients.
Guwahati's specialists help coordinate Vitrakvi access for patients across the Northeast.
Patients in other cities across India can also access Vitrakvi through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
